Lv12
98 积分 2023-07-13 加入
Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis
7小时前
已完结
Targeting lipid–protein interaction to treat Syk-mediated acute myeloid leukemia
1天前
已完结
Targeting interleukin-11 signaling, an emerging patholgical mediator in thyroid eye disease
4天前
已关闭
Therapeutic Targeting of IL-11 for Chronic Lung Disease
6天前
已完结
Redefining IL11 as a regeneration-limiting hepatotoxin and therapeutic target in acetaminophen-induced liver injury
8天前
已完结
Fibrosis in IBD: from pathogenesis to therapeutic targets
11天前
已完结
Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor
13天前
已完结
Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study
1个月前
已完结
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
1个月前
已完结
Comparison of CD30L and OX40L Reveals CD30L as a Promising Therapeutic Target in Atopic Dermatitis
1个月前
已完结
皖公网安备34019202002308
